GlassScriptPhysician profile
David Vazan
NPI 1326215435
$2,680.45
in general payments reported to CMS, 2019-2025
22 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $357 · 2021: $319 · 2022: $713 · 2023: $243 · 2024: $320 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $508.38 | 2019-2025 | Rocklatan, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $331.31 | 2019-2021 | |
| Optos, INC. | $295.56 | 2022 | |
| Sun Pharmaceutical Industries INC. | $230.82 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $194.28 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $178.29 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $164.45 | 2022-2025 | |
| Rxsight INC | $144.21 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Novartis Pharmaceuticals Corporation | $142.73 | 2019-2023 | |
| Allergan, INC. | $117.26 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $63.84 | 2019-2021 | |
| Sight Sciences, INC. | $48.62 | 2021-2024 | Tearcare System |
| Dompe US, INC. | $46.81 | 2019-2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $36.25 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $30.91 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $29.59 | 2022 | |
| Samsara Vision | $27.72 | 2024 | |
| Glaukos Corporation | $23.87 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Ocular Therapeutix, INC. | $22.79 | 2021 | |
| Amgen INC. | $17.96 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $12.87 | 2021 | |
| Ivantis, INC | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vazan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.